REMS For Opioids Still Has A Long Road Ahead; Advisory Committee Is Likely

A finalized Risk Evaluation and Mitigation Strategy for opioids is a long way off - possibly more than a year - and FDA expects additional stakeholder and industry meetings, as well as a multidisciplinary advisory committee to take place before a program is set in stone